EG628518 Inhibitors
The class of chemicals identified as Ctag2l2 inhibitors encompasses a range of compounds that can influence the activity of the protein Ctag2l2 by various mechanisms. Tunicamycin, for example, can disrupt glycosylation processes within the cell, which is essential for the proper folding and stability of proteins like Ctag2l2, particularly within the context of the EKC/KEOPS complex. Similarly, cycloheximide and emetine are known to inhibit protein synthesis by interfering with the translocation and elongation steps on ribosomes, respectively, thereby reducing the synthesis of proteins such as Ctag2l2. This can lead to a decrease in the protein's availability within the cellular milieu. Additionally, chloroquine can alter the pH and environment of organelles such as the centrosome, affecting the activity or interactions of Ctag2l2 localized in that region.
On the other hand, deoxyglucose can lead to a depletion of cellular energy levels, which can impact energy-dependent processes involving Ctag2l2. Actinomycin D binds to DNA, preventing the transcription of proteins part of the EKC/KEOPS complex, including Ctag2l2. Puromycin causes premature chain termination during protein synthesis, leading to a reduction in the full-length Ctag2l2 protein. Rapamycin can inhibit mTOR signaling, which regulates protein synthesis and, by extension, can affect the assembly or function of the EKC/KEOPS complex. Furthermore, 5-Fluorouracil can interfere with the synthesis and modification of tRNAs, processes in which Ctag2l2 is implicated. Hydroxyurea can affect DNA synthesis and repair, which in turn can alter the synthesis of the EKC/KEOPS complex proteins. Nocodazole can disrupt microtubule polymerization, which can affect the function of Ctag2l2 within the centrosome. Finally, compounds like trimethoprim, although used to target bacterial enzymes, suggest that analogs targeting human enzymes can be designed to affect similar pathways involving the EKC/KEOPS complex and Ctag2l2.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Might inhibit Ctag2l2 by disrupting the glycosylation process in the cell, which could be crucial for the proper folding or stability of the protein or its partners within the EKC/KEOPS complex. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Could inhibit Ctag2l2 by preventing its synthesis through inhibition of protein translation. This would reduce the overall levels of Ctag2l2 in the cell, potentially affecting the EKC/KEOPS complex function. | ||||||
Emetine | 483-18-1 | sc-470668 sc-470668A sc-470668B sc-470668C | 1 mg 10 mg 50 mg 100 mg | $352.00 $566.00 $1331.00 $2453.00 | ||
Might inhibit Ctag2l2 indirectly by blocking protein synthesis at the translation elongation stage, which would lower the concentration of Ctag2l2 and its associated proteins in the EKC/KEOPS complex. | ||||||
Chloroquine | 54-05-7 | sc-507304 | 250 mg | $68.00 | 2 | |
Could disrupt the function of Ctag2l2 by altering the pH and environment of cellular compartments like the centrosome where Ctag2l2 is located, possibly affecting its activity or interactions. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $65.00 $210.00 | 26 | |
Might indirectly inhibit Ctag2l2 function by depleting cellular energy levels, which could impact energy-dependent processes including the assembly or function of the EKC/KEOPS complex where Ctag2l2 is a part. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Could inhibit Ctag2l2 by binding to DNA and preventing the transcription of mRNA for proteins involved in the EKC/KEOPS complex, thereby reducing the levels of Ctag2l2 and its interaction partners. | ||||||
Puromycin | 53-79-2 | sc-205821 sc-205821A | 10 mg 25 mg | $163.00 $316.00 | 436 | |
Might inhibit Ctag2l2 by causing premature chain termination during protein synthesis, leading to a reduction in the full-length Ctag2l2 protein and potentially impacting the integrity of the EKC/KEOPS complex. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Could inhibit Ctag2l2 indirectly by inhibiting mTOR, which may decrease the synthesis of proteins that are necessary for the proper function of the EKC/KEOPS complex, thereby affecting Ctag2l2's role within the complex. | ||||||
Fluorouracil | 51-21-8 | sc-29060 sc-29060A | 1 g 5 g | $36.00 $149.00 | 11 | |
Might inhibit Ctag2l2 by interfering with the synthesis of tRNAs and their subsequent modifications, which could be crucial for the metabolic processes that Ctag2l2 is predicted to be involved in. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Could inhibit Ctag2l2 indirectly by affecting DNA synthesis and repair, which may alter the synthesis of proteins that form the EKC/KEOPS complex, thus potentially impacting the availability and function of Ctag2l2. | ||||||